Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484238 | 0.85 | LMNA (0.55) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL31006490 | 0.85 | LMNA (0.55) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL14885759 | 0.83 | LMNA (0.57) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL980972 | 0.82 | L3MBTL1 (0.44) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL31098583 | 0.81 | GAA (0.57) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL980180 | 0.81 | LMNA (0.42) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL986289 | 0.81 | HDAC6 (0.43) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL2850737 | 0.80 | KDM4E (0.53) | LMNANAPRTHDAC6ALDH1A1NPSR1 | |
| SCHEMBL14855279 | 0.79 | LMNA (0.52) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL10690356 | 0.78 | CES2 (0.61) | LMNAL3MBTL1NAPRTP4HTMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812418-B1 | DIBENZOSUBERONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-27 | — | — | EP | disclosed |
| EP-1716132-B1 | SPIRO-BENZODIOXOLES AND THEIR USE AS CB1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-25 | — | — | EP | disclosed |
| EP-1812418-A1 | DIBENZOSUBERONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-7220743-B2 | Heterocyclic CB1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7144890-B2 | Spiro-pentacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1716132-A2 | SPIRO-BENZODIOXOLES AND THEIR USE AS CB1 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006050842-A1 | DIBENZOSUBERONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100206-A1 | Heterocyclic CB1 receptor antagonists | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-05-11 | — | — | US | disclosed |
| WO-2005075450-A2 | SPIRO-BENZODIOXOLES AND THEIR USE AS CB1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| US-20050165012-A1 | Spiro-pentacyclic compounds | HOFFMANN-LA ROCHE INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100206-A1 | Heterocyclic CB1 receptor antagonists | CNR1, CNR2, HCRTR2 | LMNA 4272/4885L3MBTL1 3945/4885NAPRT 847/4885 |
| US-20050165012-A1 | Spiro-pentacyclic compounds | CNR1, CNR2, GPR119 | LMNA 2973/4885L3MBTL1 4740/4885NAPRT 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.